Abstract
Depression is an incapacitating and hardly treated psychiatric condition so the development of new drugs has been a priority for big pharmaceutical companies and academics. New molecular entities with antagonistic action on CRHR1 and V1b receptors have been developed by Sanofi-Aventis and Pfizer and showed antidepressant activities in pre-clinical models. We investigated the effectiveness…